On Location

On Location

Updates from major medical meetings in the field of hematology/oncology

New Compound Boosts Healthy Red Blood Cell Production, Lowers Anemia Burden in β-Thalassemia

ACE-536, a recombinant fusion protein containing modified activin receptor type IIB and IgG Fc, has shown promising results in the treatment of β-thalassemia, reducing the need for...

HSCT Could Become Standard of Care for HIV-Positive Patients with Lymphoma

Results from a multi-institutional trial presented at ASH 2014 debunk the common myth that HIV-positive patients with lymphoma might not be suitable for autologous hematopoietic stem cell...

Ibrutinib + Rituximab Benefits Patients With Pre-Treated Lymphoma and Leukemia

The combination of ibrutinib and rituximab is a promising treatment option for patients with relapsed or refractory blood cancers, according to results of two...

PD-1 Checkpoint Inhibitors Harness the Immune System to Treat Lymphomas

A new class of drugs, known as immune checkpoint inhibitors, is providing new perspective on how to treat relapsed and refractory lymphomas, according to...

CAR T Therapies: Engineering a Breakthrough in Lymphoma and Leukemia Treatment

Novel therapies that harness the body’s own immune cells to attack cancer cells took center stage at this year’s annual meeting. Across a variety of...

Venetoclax Plus Low-Dose Cytarabine Safe and Effective in Older Patients With Acute Myeloid Leukemia

The combination of the selective BCL-2 inhibitor venetoclax and low-dose cytarabine (LDAC) is a safe, effective option in older patients with acute myeloid leukemia...

ASH 2014 Annual Meeting Preview: The Rising Cost of Medical Care

Understanding the Problems and Exploring Solutions Health-care spending in the United States is a growing problem: in 2011, health-care spending was estimated at $2.7 trillion,...

Age, Comorbidity, Time on Chemotherapy Predict Increases in Hospitalizations, ER Visits Among CLL Patients

Researchers identified several risk factors leading to greater health-care resource use, including age, comorbidity burden, presence of adverse events, and duration of therapy, in...

Nilotinib Improves Prognosis in Elderly Patients with Ph+ ALL

For the difficult-to-treat elderly population (aged ≥55 years) with Philadelphia chromosome positive (Ph+) acute lymphocytic leukemia (ALL), combining age-adapted, low-intensity chemotherapy with nilotinib is...

Age, Sex, Timing of Treatment Response Predict Avascular Necrosis in Children with ALL

Avascular necrosis (AVN), a disorder resulting from a temporary or permanent loss of blood supply to the bone, is one of the most serious...
Advertisement

Current Issue

March 2019, Volume 5, Issue 4

This issue features a look at the misconceptions about travel-associated blood clots, the treatment of young patients with myeloma, and more.